Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Growth hormone plus GnRHa for adult height in short adolescents
NL-OMON23928Active, not recruiting
- Sponsor
- Pfizer
- Start
- Oct 1993
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of somatropin and triptorelin in Idiopathic Short Stature (ISS) and growth disorder, sponsored by Pfizer. Primary endpoint: Change in height SDS from baseline to final height. Started Oct 1993; status: active, not recruiting.
02
Drugs
somatropintriptorelin
03
Conditions
Idiopathic Short Stature (ISS)growth disorder
Beyond the preview
Go deeper on NL-OMON23928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23928.